Company Overview
FibroBiologics, Inc. operates as a clinical-stage biotechnology entity dedicated to the development and commercialization of fibroblast-based therapies designed for patients suffering from chronic diseases. The company's specific product pipeline includes CYWC628, which has successfully completed pre-clinical trials for the treatment of wounds. This firm functions within the broader healthcare sector and the specific sub-sector of biotechnology, an industry characterized by high research and development costs and significant regulatory hurdles before products reach market. The company currently maintains a market capitalization of $669,982 and employs 15 individuals to execute its strategic initiatives. These valuation and personnel metrics indicate that FibroBiologics, Inc. is a micro-cap entity with a very limited operational footprint, reflecting the early-stage nature of its clinical development efforts and the substantial capital requirements typical for biotechnology firms prior to commercialization.
Financial Health
The company reports no annual revenue over the trailing twelve-month period, while simultaneously reporting a net income of $-18,646,000 and an EBITDA of $-16,405,000. The substantial gap between the reported revenue of N/A and the significant negative net income reveals a cost structure dominated by operational expenses and research expenditures rather than sales costs, which is standard for clinical-stage biotechnology companies generating no commercial sales. The free cash flow stands at $-9,968,125, indicating that the company is burning through its cash reserves to fund its development activities and lacks the current financial flexibility to sustain operations without external capital infusion. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which mathematically reflects the absence of revenue against which to calculate profitability ratios, rather than an efficient cost structure. On the balance sheet, the company holds $4.89M in cash against $2.41M in debt, resulting in a debt-to-equity ratio of 39.15. Although the company holds more liquid assets than debt obligations, the high debt-to-equity ratio suggests a leveraged capital structure relative to its equity base, creating potential sensitivity to interest rate changes or liquidity constraints. The current ratio is 3.61, which indicates a strong position in short-term liquidity, as the company possesses more than three times the current assets required to cover its current liabilities. Return on Equity is -419.4% and Return on Assets is -79.8%, metrics that reveal management is not generating positive returns on shareholder capital or the company's asset base, consistent with the heavy investment phase of a pre-revenue biotechnology firm.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is -0.73, a metric that implies the market is pricing in continued negative earnings or expects a turnaround in profitability that has not yet materialized in historical data. The price-to-book ratio is 2.11, indicating that the market values the company at more than double its book value, which may reflect investor optimism regarding the potential value of its intellectual property and pipeline assets despite current financial losses. The price-to-sales ratio is N/A because there is no revenue to measure, and the EV/EBITDA stands at -0.66, suggesting that enterprise value is being assessed relative to negative earnings power. The stock's 52-week trading range has a high of $1.53 and a low of $0.19, and without a specific current price provided in the source data, the relative position cannot be calculated, but the wide range suggests high historical volatility. The beta value is -0.67, which is an anomalous negative figure for an equity security, indicating a price movement pattern that has historically moved inversely to the broader market or is heavily influenced by specific idiosyncratic factors rather than general market sentiment.
Growth & Income
The revenue growth year-over-year is N/A, as there is no revenue history to establish a growth rate, and earnings growth year-over-year is also N/A for similar reasons. Since the company has no revenue or earnings, there is no growth trajectory to compare earnings growth against revenue growth, a comparison that is typically used to assess operational leverage in mature companies. As a non-dividend payer, the company does not distribute a dividend yield or utilize a payout ratio, meaning it reinvests all available resources, including its cash reserves, back into research and development to advance its pipeline. The overall growth and income profile for FibroBiologics, Inc. is characterized by a complete absence of current commercial generation and income distribution, relying entirely on future clinical milestones to unlock value.